FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

632 letters match. Newest first.

  1. Saruhan Kimya Ve Temizlik Urunleri Sanayi Ticaret Anonim Sirketi Corlu Subesi

    FDA found manufacturing violations at Turkish OTC drug maker, including missing identity, release, and stability testing for hand sanitizers.

    High risk
  2. Global Pharma Healthcare Private Limited

    FDA warned Global Pharma Healthcare that non-sterile artificial tears and eye ointment from its India plant were tied to a Pseudomonas outbreak with four deaths.

    High risk
  3. ALI Pharmaceutical Manufacturing, LLC

    FDA says ALI Pharmaceutical Manufacturing failed to validate and control its porcine thyroid drug substance process, making the drug substance adulterated.

    High risk
  4. Handock Cosmetics Co., Ltd.

    FDA warns Handock Cosmetics over manufacturing quality failures and unapproved/mislabeled hand sanitizers from South Korea.

    High risk
  5. Sun Pharmaceutical Industries Ltd.

    FDA warns Sun Pharmaceutical over CGMP violations in sterile injectable manufacturing at its Halol, India facility.

    High risk
  6. Seoul Cosmetics Co., Ltd.

    FDA warned Seoul Cosmetics, a South Korean drug maker, over poor manufacturing quality and unapproved OTC drugs.

    High risk
  7. Kor-Chem, Inc.

    Kor-Chem, Inc. made OTC hand sanitizer drugs with manufacturing violations, including shared equipment with industrial chemicals and missing identity and microbial testing.

    High risk
  8. PureChemPros LLC

    FDA warns PureChemPros over manufacturing quality failures and unapproved, misbranded hand sanitizer and hydrogen peroxide drugs.

    High risk
  9. CVS Health

    FDA told CVS Health its unapproved Pink Eye Relief Drops are an illegal new drug made by a manufacturer with serious quality violations.

    High risk
  10. TRP Company, Inc

    FDA warns TRP Company that its homeopathic eye drops and ointments are unapproved new drugs and may be adulterated.

    High risk
  11. Walgreens Boots Alliance, Inc.

    FDA warned Walgreens over three store-brand eye drops sold as unapproved new drugs and tied to contract manufacturer manufacturing violations.

    High risk
  12. Similasan AG

    Similasan AG's ophthalmic drugs are unapproved new drugs and violate CGMP (manufacturing quality rules), FDA says.

    High risk
  13. Safecor Health, LLC

    FDA warned drug repackager Safecor Health over CGMP failures that let tablets from other drugs contaminate packaging lines.

    High risk
  14. Green Pharmaceutical Co. Ltd.

    FDA warns South Korea's Green Pharmaceutical over OTC drug CGMP failures, including missing identity testing and weak quality unit.

    High risk
  15. Lex Inc.

    FDA warns Lex Inc. of Medley, Florida, that its over-the-counter drugs are adulterated because manufacturing rules were not met, including missing toxic-ingredient testing.

    High risk
  16. Gadal Laboratories Inc.

    FDA warned Gadal Laboratories of CGMP violations at its Miami drug plant, including unqualified suppliers and contamination risks in pediatric OTC drugs.

    High risk
  17. Cosmobeauti Laboratories & Manufacturing Inc.

    FDA warns Cosmobeauti Laboratories over manufacturing rule violations for OTC sunscreen drugs, including backdated batch records and missing microbial testing.

    High risk
  18. K.C. Pharmaceuticals Inc.

    FDA warned K.C. Pharmaceuticals after inspections found manufacturing rule violations in sterile ophthalmic drugs, including inadequate contamination controls and cleaning validation.

    High risk
  19. K. Boeun Pharmaceutical Co., Ltd.

    K. Boeun Pharmaceutical's OTC drugs were cited for CGMP violations, including missing identity tests for DEG/EG-risk components and inadequate quality unit.

    High risk
  20. International Laboratories Corp. Ltd.

    International Laboratories Corp. Ltd. failed manufacturing-practice rules for OTC drugs, including component identity testing and quality-unit oversight.

    High risk
  21. CalmCo LLC previously named Ketomi LLC

    FDA warns CalmCo that Colic Calm and Colic Calm + are unapproved new drugs for infants.

    High risk
  22. ALVA-AMCO Pharmacal Companies, LLC

    FDA warns ALVA-AMCO that Nauzene Kids, a children’s nausea drug, is an unapproved new drug.

    High risk
  23. Laavo Clean, S.A. de C.V.

    Laavo Clean's alcohol-free hand sanitizers had wrong benzalkonium chloride strength and were refused at US border.

    High risk
  24. Denison Pharmaceuticals, LLC

    Denison Pharmaceuticals was cited for manufacturing quality failures, contamination risks, and unapproved infant/homeopathic drugs.

    High risk
  25. Fancystage Unipessoal, LDA

    Portugal OTC drug maker Fancystage Unipessoal skipped identity testing of high-risk ingredients and lacked quality-unit control, FDA says.

    High risk
  26. Avaria Health & Beauty Corp.

    FDA cites Avaria Health & Beauty for manufacturing-rule violations in OTC drugs, including missing glycerin identity testing and weak quality unit.

    High risk
  27. Tan Alize Kozmetik Ve Temizlik Urunleri

    FDA warns Turkish OTC drug maker Tan Alize over missing glycerin identity testing and a weak quality unit; import alert issued.

    High risk
  28. LCC Ltd.

    LCC Ltd., an OTC drug maker, lacked identity testing for risky ingredients and adequate quality oversight, FDA says.

    High risk
  29. Suhan Aerosol

    Suhan Aerosol, an Indian OTC drug maker, failed to test high-risk ingredients for toxic diethylene/ethylene glycol and lacked quality oversight.

    High risk
  30. Skyline Herbals Private Limited

    FDA warns India's Skyline Herbals after it ignored records requests for OTC drugs including toothpaste; all its drugs hit Import Alert 66-79.

    High risk
  31. Daxal Cosmetics Private Limited

    FDA warns Daxal Cosmetics for refusing records on over-the-counter drugs, including toothpaste, at risk for diethylene glycol and ethylene glycol contamination.

    High risk
  32. Orchid Lifesciences

    FDA warns Orchid Lifesciences over over-the-counter drug testing gaps and weak quality unit.

    High risk
  33. Intas Pharmaceuticals Limited

    FDA warned Intas Pharmaceuticals about serious manufacturing-quality violations, including data integrity failures and inaccurate environmental monitoring, at its India drug plant.

    High risk
  34. Baxter Healthcare Corporation

    FDA warned Baxter over CGMP violations at its India plant, including inadequate endotoxin and visual inspection investigations for sterile injectables.

    High risk
  35. Centaur Pharmaceuticals Private Ltd.

    FDA says Centaur Pharmaceuticals drugs were adulterated due to inadequate cleaning and cross-contamination.

    High risk
  36. Medgel Private Limited

    FDA cited Medgel Private Limited, an Indian OTC drug maker, for manufacturing violations including poor investigations and data integrity failures.

    High risk
  37. Iso-Tex Diagnostics, Inc.

    FDA warns Iso-Tex Diagnostics over manufacturing violations that risk contamination of sterile radiopharmaceutical drugs.

    High risk
  38. Avlon Industries, Inc.

    FDA warned Avlon Industries that its over-the-counter drug manufacturing broke quality rules, citing missing identity tests for high-risk glycerin/propylene glycol and validation failures.

    High risk
  39. LXR Biotech, LLC

    FDA says LXR Biotech, a contract maker of an OTC drug, shipped batches without testing components or finished product.

    High risk
  40. Jamol Laboratories, Inc.

    FDA found Jamol Laboratories making a nasal emollient under insanitary conditions and without adequate quality control, lab testing, or process validation.

    High risk
  41. Fuller Industries Inc.

    FDA warns Fuller Industries over current good manufacturing practice violations in OTC hand soaps and sanitizers, including quality oversight and ingredient testing.

    High risk
  42. Centaur Pharmaceuticals Private Ltd.

    FDA warns Centaur Pharmaceuticals over manufacturing practice failures in active ingredients, including records and cleaning.

    High risk
  43. NeilMed Pharmaceuticals Inc.

    FDA warned NeilMed Pharmaceuticals that its OTC drug manufacturing had current good manufacturing practice violations, including missing glycerin identity testing and dirty equipment.

    High risk
  44. Chengdu KeCheng Fine Chemicals Co., Ltd.

    FDA placed Chengdu KeCheng's APIs on import alert after it ignored FDA records requests.

    High risk
  45. Mr. Lulu LLC

    FDA warned Mr. Lulu LLC of Claremont, California, that its OTC sunscreen drops were adulterated: no release testing, no identity testing, no batch records.

    High risk
  46. RemedyRepack, Inc.

    RemedyRepack, a drug repackager in Indiana, Pennsylvania, failed CGMP, including cleaning and beta-lactam cross-contamination controls.

    High risk
  47. New England Life Care, Inc. dba Advanced Compounding Solutions

    FDA cites Advanced Compounding Solutions for insanitary sterile-drug production and CGMP failures after a 2022 inspection.

    High risk
  48. Champaklal Maganlal Homeo Pharmacy Private Limited

    FDA says Champaklal Maganlal Homeo Pharmacy's Bebelyn diarrhea and colic products are unapproved new drugs for infants.

    High risk
  49. Sure-Biochem Laboratories, LLC

    FDA says contract lab Sure-Biochem missed Burkholderia cepacia in drug samples and cites broad CGMP failures.

    High risk
  50. Pharmedica USA, LLC

    FDA found Pharmedica made ophthalmic and nasal drugs under insanitary conditions without required sterile controls.

    High risk